Spots Global Cancer Trial Database for hodgkin disease
Every month we try and update this database with for hodgkin disease cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Safety Study of SGN-35T in Adults With Advanced Cancers | NCT06120504 | Lymphoma, T-Cel... Hodgkin Disease Lymphoma, T-Cel... Lymphoma, Large... Lymphoma, Large... Lymphoma, Non-H... | SGN-35T | 18 Years - | Seagen Inc. | |
| Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease | NCT00000626 | HIV Infections Hodgkin's Disea... | Vinblastine sul... Dacarbazine Filgrastim Bleomycin sulfa... Doxorubicin hyd... | 12 Years - | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma | NCT00026208 | Lymphoma, Hodgk... Lymphoma Hodgkin Disease Lymphoma: Hodgk... | Vincristine Cyclophosphamid... Doxorubicin Prednisone Bleomycin Etoposide Low-dose radiot... | 18 Years - 70 Years | Stanford University | |
| Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies | NCT02639559 | Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Non-Hodgkin's L... Non-Hodgkin Lym... Hodgkin Disease Hodgkins Diseas... Hodgkin's Disea... Multiple Myelom... Myelodysplastic... Myeloproliferat... | BL-8040 Leukapheresis Hematopoietic c... | 18 Years - 75 Years | Washington University School of Medicine | |
| A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma | NCT02979522 | Hodgkin Disease | Brentuximab ved... Doxorubicin Vinblastine Dacarbazine | 5 Years - 17 Years | Takeda | |
| Tissue Collection for Studies of Lymph Cancer | NCT01676805 | Hodgkin Disease Lymphoma, Non-H... Multiple Myelom... Lymphomatoid Gr... Leukemia-Lympho... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant | NCT03739502 | AML NHL Hodgkin Disease All Myelodysplastic... | Hyperbaric oxyg... | 18 Years - 70 Years | University of Rochester | |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma | NCT05255601 | Lymphoma, Non-H... Hodgkin Disease | Relatlimab Nivolumab | - 30 Years | Bristol-Myers Squibb | |
| A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma | NCT00636311 | Hodgkin Disease | Ifosfamide, Gem... Bortezomib + IG... | 18 Years - 65 Years | Istituto Clinico Humanitas | |
| A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies | NCT00051597 | Hodgkin Disease Lymphoma, Large... Sarcoma, Kaposi Lymphoma, T-Cel... Lymphoma, B-Cel... | SGN-30 (monoclo... | 18 Years - | Seagen Inc. | |
| Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease | NCT00388349 | Hodgkin Disease Hodgkin's Lymph... Lymphoma | Gemcitabine Vinorelbine Carmustine Etoposide Cyclophosphamid... Autologous HCT | 18 Years - 70 Years | Stanford University | |
| A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248) | NCT00779584 | Hodgkin Disease Lymphoma, Non-H... Neoplasms | MK-8776 Gemcitabine | 18 Years - | Merck Sharp & Dohme LLC | |
| The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD) | NCT00444912 | Non-Hodgkin Lym... Hodgkin Disease | G-CSF plus pler... G-CSF plus pler... rituximab | 18 Years - 70 Years | Sanofi | |
| Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A | NCT01858922 | Hodgkin Disease | ABVE-PC DECA | - | Baylor College of Medicine | |
| Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A | NCT01858922 | Hodgkin Disease | ABVE-PC DECA | - | Baylor College of Medicine | |
| A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | NCT01716806 | Hodgkin Disease Peripheral T Ce... | brentuximab ved... bendamustine dacarbazine nivolumab | 18 Years - | Seagen Inc. | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE | NCT02686346 | Hodgkin Disease | Brentuximab Ved... Etoposide Carboplatine Ifosfamide | 18 Years - 65 Years | The Lymphoma Academic Research Organisation | |
| Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) | NCT02181738 | Hodgkin Disease | Nivolumab Doxorubicin Vinblastine Dacarbazine | 18 Years - | Bristol-Myers Squibb | |
| Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease | NCT00058773 | Hodgkin Disease Non-Hodgkins Ly... | Infusion of EBV... | - | Baylor College of Medicine | |
| A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma | NCT02979522 | Hodgkin Disease | Brentuximab ved... Doxorubicin Vinblastine Dacarbazine | 5 Years - 17 Years | Takeda | |
| Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT) | NCT01745354 | Lymphoma, Non-H... Hodgkin Disease | SD-101 Local Radiation | 18 Years - | Stanford University | |
| Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) | NCT01657331 | Hodgkin Lymphom... Anaplastic Larg... | Brentuximab Ved... Bendamustine Neulasta | 18 Years - | Columbia University | |
| Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer | NCT00039676 | Waldenstrom Mac... Chronic Lymphoc... Hodgkin Disease NonHodgkin Lymp... Mixed Lymphopro... | 11 Months - | National Institutes of Health Clinical Center (CC) | ||
| Cytogenetic Analysis of Bone Marrow Specimen Prior to High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease | NCT00534820 | Lymphoma, Non-H... Hodgkin Disease | Cytogenetic Ana... | - | King Faisal Specialist Hospital & Research Center | |
| Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies | NCT00514722 | Acute Myeloid L... Myelodysplasia Acute Lymphobla... Chronic Myeloge... Multiple Myelom... Lymphoma, Large... Lymphoma, Mantl... Lymphoma, T-Cel... T-NK Cell Lymph... Hodgkin Disease | umbilical cord ... | 18 Years - 55 Years | University of California, San Francisco | |
| Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) | NCT02181738 | Hodgkin Disease | Nivolumab Doxorubicin Vinblastine Dacarbazine | 18 Years - | Bristol-Myers Squibb | |
| Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease | NCT00388349 | Hodgkin Disease Hodgkin's Lymph... Lymphoma | Gemcitabine Vinorelbine Carmustine Etoposide Cyclophosphamid... Autologous HCT | 18 Years - 70 Years | Stanford University | |
| Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma | NCT01195766 | Hodgkin Disease | Ofatumumab | 18 Years - 75 Years | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | |
| Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Cases | NCT00538551 | Hodgkin Disease Lymphoma, Non-H... | Database | 14 Years - 85 Years | King Faisal Specialist Hospital & Research Center | |
| Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic Malignacies | NCT02885038 | Lymphoma Multiple Myelom... Lymphocytic Leu... Hodgkin Disease | Platelet concen... | 18 Years - | Etablissement Français du Sang | |
| Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols | NCT02682667 | Multiple Myelom... Lymphoma, Non-H... Leukemia-Lympho... Hodgkin Disease Non-Small Cell ... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | ||
| A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity | NCT02567851 | Hodgkin Disease | Brentuximab Ved... | 16 Years - | University of Birmingham | |
| Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma | NCT00724984 | Lymphoma Hodgkin Disease Lymphoma, Non-H... | PCI-24781 | 18 Years - | Pharmacyclics LLC. | |
| A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer | NCT01149668 | Lymphoma Non-Hodgkin's L... Hodgkin Disease Multiple Myelom... Leukemia Lymphocytic | PCI-24781 | 18 Years - | Pharmacyclics LLC. | |
| Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT | NCT00534989 | Lymphoma, Non-H... Hodgkin Disease | FDG PET | - | King Faisal Specialist Hospital & Research Center | |
| Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality | NCT02378337 | Malignant Neopl... Hodgkin Disease Non-Hodgkin Lym... Malignant Neopl... Malignant Neopl... Secondary Neopl... Malignant Melan... Malignant Neopl... | Image quantify | 18 Years - | Hospital Sao Rafael | |
| A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia | NCT02733042 | Lymphoma Leukemia, Lymph... | Durvalumab Lenalidomide Rituximab Ibrutinib Bendamustine | 18 Years - | Celgene | |
| Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies | NCT00145613 | Acute Lymphobla... Acute Myeloid L... Secondary AML Myelodysplastic... Secondary MDS Chronic Myeloid... Juvenile Myelom... Paroxysmal Noct... Lymphoma, Non-H... Hodgkin Disease | Stem Cell Trans... Miltenyi Biotec... Systemic chemot... | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) | NCT02181738 | Hodgkin Disease | Nivolumab Doxorubicin Vinblastine Dacarbazine | 18 Years - | Bristol-Myers Squibb | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL | NCT01333046 | Hodgkin Lymphom... Non-Hodgkin Lym... Hodgkin Disease | Antigen-Escalat... Dose-Escalation... azacytidine and... Pediatric multi... | 18 Years - | Baylor College of Medicine | |
| Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene | NCT01875237 | Leukemia Myeloma Myeloproliferat... | Fludarabine Melphalan Alemtuzumab Stem Cell infus... Tacrolimus Mini Methotrexa... G-CSF Donor Lymphocyt... AP1903 Methylprednisol... Questionnaire | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma | NCT04459416 | Multiple Myelom... Hodgkin Disease Non-Hodgkin Lym... | Acupuncture opioid Assessments | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| High Dose Chemotherapy Followed By PBSC Rescue for HD | NCT00186251 | Hodgkin Disease | high dose chemo... | 4 Weeks - 70 Years | Stanford University | |
| Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients | NCT01121120 | Lymphoma, Non-H... Hodgkin Disease Multiple Myelom... | TXA127 Placebo | 18 Years - | Tarix Pharmaceuticals | |
| Feasibility and Agreement of Remote Evaluation of Resting Heart Rate and Heart Rate Variability in Survivors of Hodgkin Lymphoma Treated With Chest Radiation (PILOT STUDY-SURVIVOR) | NCT03838627 | Hodgkin Disease | 18 Years - | St. Jude Children's Research Hospital | ||
| A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation | NCT00275262 | Hodgkin Disease Lymphoma, Non-H... Multiple Myelom... Mantle Cell Lym... | Leuprolide acet... Matched placebo | 18 Years - 65 Years | Abbott | |
| Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL | NCT01333046 | Hodgkin Lymphom... Non-Hodgkin Lym... Hodgkin Disease | Antigen-Escalat... Dose-Escalation... azacytidine and... Pediatric multi... | 18 Years - | Baylor College of Medicine | |
| Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas | NCT02181218 | Lymphoma, T-Cel... Lymphoma, T-Cel... Hodgkin Disease Lymphoma, Large... | Romidepsin Gemcitabine Oxaliplatin Dexamethasone Pegfilgrastim | 18 Years - | Washington University School of Medicine | |
| A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma | NCT02979522 | Hodgkin Disease | Brentuximab ved... Doxorubicin Vinblastine Dacarbazine | 5 Years - 17 Years | Takeda | |
| Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers | NCT04072393 | Lung Cancer Esophageal Canc... Thoracic Cancer Hodgkin Lymphom... Hodgkin Disease Non-hodgkin Lym... Sarcoma Thymoma Breast Cancer | Home-based card... | 18 Years - | Washington University School of Medicine | |
| Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols | NCT02682667 | Multiple Myelom... Lymphoma, Non-H... Leukemia-Lympho... Hodgkin Disease Non-Small Cell ... | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | ||
| Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells | NCT00398411 | Hodgkin Disease Non-Hodgkin Lym... Multiple Myelom... Bacteremia | moxifloxacin placebo | 18 Years - 75 Years | University of Cologne | |
| Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients | NCT00562224 | Neoplasms by Si... Lymphoma, Non-h... Hodgkin Disease Multiple Myelom... Leukemia, Lymph... | PCI-24781 | 18 Years - | Pharmacyclics LLC. | |
| Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma | NCT00026208 | Lymphoma, Hodgk... Lymphoma Hodgkin Disease Lymphoma: Hodgk... | Vincristine Cyclophosphamid... Doxorubicin Prednisone Bleomycin Etoposide Low-dose radiot... | 18 Years - 70 Years | Stanford University | |
| Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease | NCT00225173 | Hodgkin Disease | Doxorubicin Vinblastine Cyclophosphamid... Etoposide Vincristine Bleomycin Gemcitabine Vinorelbine Prednisone | 18 Years - 70 Years | Stanford University | |
| Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL | NCT01333046 | Hodgkin Lymphom... Non-Hodgkin Lym... Hodgkin Disease | Antigen-Escalat... Dose-Escalation... azacytidine and... Pediatric multi... | 18 Years - | Baylor College of Medicine | |
| Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma | NCT01555853 | Lymphoma, Non-H... Hodgkin Disease | Abraxane | 18 Years - | Washington University School of Medicine | |
| Hodgkin's Disease and Chemotherapy Before 40 Years | NCT06116929 | Hodgkin Disease | Morphological a... Neuropsychologi... | 18 Years - 40 Years | Lille Catholic University | |
| A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy | NCT00261677 | Anemia Hodgkin Disease Leukemia Lymphoma, Non-h... | epoetin alfa | 5 Years - 18 Years | Ortho Biotech Products, L.P. | |
| Safety Study of SEA-CD40 in Cancer Patients | NCT02376699 | Carcinoma, Non-... Carcinoma, Squa... Hodgkin Disease Lymphoma Lymphoma, B-Cel... Lymphoma, Folli... Lymphoma, Large... Melanoma Neoplasm Metast... Neoplasms, Head... Neoplasms, Squa... Non-Small Cell ... Non-Small Cell ... Non-small Cell ... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell N... Lymphoma, Non-H... Pancreatic Aden... | Intravenous (IV... Pembrolizumab Subcutaneous (S... Gemcitabine Nab-paclitaxel | 18 Years - | Seagen Inc. | |
| A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors. | NCT04671693 | Late Effects Testicular Germ... Non-Metastatic ... Soft Tissue Sar... Osteosarcoma Ewing's Sarcoma Acute Myeloid L... Hodgkin Disease Non Hodgkin Lym... | PASCA intervent... | 18 Years - 65 Years | Centre Leon Berard | |
| Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors | NCT03935282 | Breast Neoplasm Prostatic Neopl... Colorectal Neop... Endometrial Neo... Hodgkin Disease Non Hodgkin Lym... | AH-HA Tool in t... | 18 Years - | Wake Forest University Health Sciences | |
| Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma | NCT00540007 | Hodgkin Disease | Lenalidomide | 18 Years - | Washington University School of Medicine | |
| Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies | NCT00145613 | Acute Lymphobla... Acute Myeloid L... Secondary AML Myelodysplastic... Secondary MDS Chronic Myeloid... Juvenile Myelom... Paroxysmal Noct... Lymphoma, Non-H... Hodgkin Disease | Stem Cell Trans... Miltenyi Biotec... Systemic chemot... | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| Brazilian Prospective Hodgkin Lymphoma Registry | NCT02589548 | Hodgkin Lymphom... Hodgkin Disease | 12 Years - 100 Years | Universidade Federal do Rio de Janeiro | ||
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma | NCT05255601 | Lymphoma, Non-H... Hodgkin Disease | Relatlimab Nivolumab | - 30 Years | Bristol-Myers Squibb | |
| Safety Study of SEA-CD40 in Cancer Patients | NCT02376699 | Carcinoma, Non-... Carcinoma, Squa... Hodgkin Disease Lymphoma Lymphoma, B-Cel... Lymphoma, Folli... Lymphoma, Large... Melanoma Neoplasm Metast... Neoplasms, Head... Neoplasms, Squa... Non-Small Cell ... Non-Small Cell ... Non-small Cell ... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell N... Lymphoma, Non-H... Pancreatic Aden... | Intravenous (IV... Pembrolizumab Subcutaneous (S... Gemcitabine Nab-paclitaxel | 18 Years - | Seagen Inc. | |
| Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients | NCT01141959 | Leukemia Hodgkin Disease Non-Hodgkin Lym... Myelodysplastic... Multiple Myelom... | 18 Years - | Fred Hutchinson Cancer Center | ||
| Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma | NCT02867618 | Hodgkin Disease Lymphoma, Non-h... | Carfilzomib TGR-1202 | 18 Years - | Columbia University | |
| Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET | NCT00188149 | Hodgkin Disease | Combined chemot... Radiation thera... | 16 Years - 75 Years | University Hospital Carl Gustav Carus | |
| Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma | NCT01207921 | Hodgkin Disease | Lenalidomide | 18 Years - | Washington University School of Medicine | |
| Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells | NCT00398411 | Hodgkin Disease Non-Hodgkin Lym... Multiple Myelom... Bacteremia | moxifloxacin placebo | 18 Years - 75 Years | University of Cologne | |
| Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma | NCT04459416 | Multiple Myelom... Hodgkin Disease Non-Hodgkin Lym... | Acupuncture opioid Assessments | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma | NCT05255601 | Lymphoma, Non-H... Hodgkin Disease | Relatlimab Nivolumab | - 30 Years | Bristol-Myers Squibb | |
| Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma | NCT00903890 | Hodgkin Disease Lymphoma, Non-H... | Survey | 18 Years - | University of Rochester | |
| High Dose Chemotherapy Followed By PBSC Rescue for HD | NCT00186251 | Hodgkin Disease | high dose chemo... | 4 Weeks - 70 Years | Stanford University | |
| Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients | NCT01764230 | Hodgkin Lymphom... Hodgkin Disease | triptorelin | 18 Years - 35 Years | Masaryk University | |
| Personalised Program for Women Treated for Hodgkin Disease | NCT01188915 | Hodgkin Disease Breast Cancer | intensive scree... | 18 Years - | Institut Paoli-Calmettes |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
